April 27, 2007
New treatment targets thrush
A new treatment for the Candida species of fungi that can cause thrush and sepsis – a life-threatening infection which can lead to fever, hypotension and shock – has been found to be effective as existing remedies.
The drug – micafungin – was found to work as well as liposomal amphotericin B and caused fewer side effects, scientists report today in the online edition of the Lancet medical journal.
Infections have become increasingly prevalent over the past few years and there are a number of problems associated with established treatments.
Researchers led by Oliver Cornely, of The University Hospital of Cologne, tested the two drugs against the infections candidaemia and invasive candidosis.
Studies were carried out at 115 sites in Europe, India, Brazil, North America, Thailand, South Africa, and Australia.
The 531 patients were split into two groups and given either micafungin 100mg per day or liposomal amphotericin B 3 mg per kg body weight daily.
Fewer problems were associated with micafungin. Patients receiving liposomal amphotericin B had more problems with kidney infections and with drug administration.
“Our results establish micafungin as a treatment option for first-line therapy of candidaemia and invasive candidosis,” the researchers conclude